Redhill Biopharma Ltd
RDHL1.080USD
-0.190-14.96%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
3.60MMarket Cap
0.31P/E TTM
More Details of Redhill Biopharma Ltd Company
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Redhill Biopharma Ltd Info
Ticker SymbolRDHL
Company nameRedhill Biopharma Ltd
IPO dateFeb 01, 2011
CEOMr. Dror Ben-Asher
Number of employees35
Security typeDepository Receipt
Fiscal year-endFeb 01
Address21 Ha'arba'a St.
CityTEL AVIV-YAFO
Stock exchangeNASDAQ Capital Market Consolidated
CountryIsrael
Postal code6473921
Phone97235413131
Websitehttps://www.redhillbio.com/
Ticker SymbolRDHL
IPO dateFeb 01, 2011
CEOMr. Dror Ben-Asher
Company Executives of Redhill Biopharma Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Shmuel Cabilly, Ph.D.
Dr. Shmuel Cabilly, Ph.D.
Independent Director
Independent Director
--
--
Ms. Patricia Anderson
Ms. Patricia Anderson
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Razi Ingber
Mr. Razi Ingber
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alexandra Okmian
Mr. Alexandra Okmian
Investor Relations
Investor Relations
--
--
Mr. Adi Frish
Mr. Adi Frish
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
--
--
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Reza Fathi, Ph.D.
Dr. Reza Fathi, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Mr. Ofer Tsimchi
Mr. Ofer Tsimchi
Independent Director
Independent Director
--
--
Dr. Kenneth Reed, M.D.
Dr. Kenneth Reed, M.D.
Independent Director
Independent Director
--
--
Mr. Guy Goldberg, J.D.
Mr. Guy Goldberg, J.D.
Chief Business Officer
Chief Business Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Shmuel Cabilly, Ph.D.
Dr. Shmuel Cabilly, Ph.D.
Independent Director
Independent Director
--
--
Ms. Patricia Anderson
Ms. Patricia Anderson
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Razi Ingber
Mr. Razi Ingber
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alexandra Okmian
Mr. Alexandra Okmian
Investor Relations
Investor Relations
--
--
Mr. Adi Frish
Mr. Adi Frish
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
--
--
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Nov 4
Updated: Tue, Nov 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Gagnon Securities LLC
0.54%
UBS Financial Services, Inc.
0.24%
Desjardins Securities Inc.
0.10%
SBI Securities Co., Ltd.
0.06%
Morgan Stanley & Co. LLC
0.05%
Other
99.01%
Shareholders
Shareholders
Proportion
Gagnon Securities LLC
0.54%
UBS Financial Services, Inc.
0.24%
Desjardins Securities Inc.
0.10%
SBI Securities Co., Ltd.
0.06%
Morgan Stanley & Co. LLC
0.05%
Other
99.01%
Shareholder Types
Shareholders
Proportion
Investment Advisor
0.30%
Research Firm
0.23%
Other
99.47%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
37
105.43K
3.17%
-17.28K
2025Q2
39
100.72K
4.39%
-24.30K
2025Q1
45
100.27K
5.67%
-27.27K
2024Q4
61
86.70K
6.77%
-35.73K
2024Q3
77
75.64K
5.91%
-52.57K
2024Q2
82
147.72K
11.56%
-10.64K
2024Q1
84
175.94K
13.78%
+109.25K
2023Q4
94
19.30K
14.67%
-65.78K
2023Q3
106
74.17K
44.30%
+53.53K
2023Q2
113
26.79K
29.96%
+840.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
UBS Financial Services, Inc.
7.99K
0.24%
+7.99K
+399250.00%
Jun 30, 2025
Desjardins Securities Inc.
3.39K
0.1%
--
--
Jun 30, 2025
SBI Securities Co., Ltd.
2.00K
0.06%
+2.00K
+39980.00%
Jun 30, 2025
Morgan Stanley & Co. LLC
1.80K
0.05%
+1.79K
+16263.64%
Jun 30, 2025
Rhumbline Advisers Ltd. Partnership
1.77K
0.05%
+380.00
+27.38%
Jun 30, 2025
BofA Global Research (US)
303.00
0.01%
--
--
Jun 30, 2025
Raymond James Financial Services Advisors, Inc.
204.00
0.01%
+204.00
--
Jun 30, 2025
GAMMA Investing LLC
135.00
0%
-1.93K
-93.45%
Sep 30, 2025
Group One Trading, L.P.
11.00
0%
-11.00
-50.00%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
Date
Type
Ratio
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
